📣 VC round data is live. Check it out!

Illumina Valuation Multiples

Discover Illumina's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Philips, Mettler Toledo, Halma, Mindray and more.

Illumina Overview

About Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.


Founded

1998

HQ

United States

Employees

10.1K

Financials (LTM)

Revenue: $4B
EBITDA: $1B

EV

$26B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Illumina Financials

Illumina reported last 12-month revenue of $4B and EBITDA of $1B.

In the same LTM period, Illumina generated $3B in gross profit, $1B in EBITDA, and $777M in net income.

Revenue (LTM)


Illumina P&L

In the most recent fiscal year, Illumina reported revenue of $4B and EBITDA of $1B.

Illumina is profitable as of last fiscal year, with gross margin of 66%, EBITDA margin of 34%, and net margin of 20%.

See analyst estimates for Illumina
LTMLast FY202320242025202620272028
Revenue$4B$4B$5B$4B$4B
Gross Profit$3B$3B$3B$3B$3B
Gross Margin68%66%65%65%66%
EBITDA$1B$1B($4B)($725M)$1B
EBITDA Margin28%34%(85%)(17%)34%
EBIT Margin23%23%8%14%19%
Net Profit$777M$850M($4B)($1B)$850M
Net Margin18%20%(96%)(28%)20%
Net Debt-$571M---

Financial data powered by Morningstar, Inc.

Illumina Stock Performance

Illumina has current market cap of $25B, and enterprise value of $26B.

Market Cap Evolution


Illumina's stock price is $164.40.

Illumina share price increased by 0.9% in the last 30 days, and by 72.3% in the last year.

Illumina has an EPS (earnings per share) of $5.62.

See more trading valuation data for Illumina
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$26B$25B0.9%0.9%33.4%72.3%$5.62

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Illumina Valuation Multiples

Illumina trades at 5.9x EV/Revenue multiple, and 21.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Illumina

EV / Revenue (LTM)


Illumina Financial Valuation Multiples

As of June 2, 2026, Illumina has market cap of $25B and EV of $26B.

Illumina has a P/E ratio of 32.0x.

LTMLast FY202320242025202620272028
EV/Revenue5.9x6.0x5.7x6.0x6.0x
EV/EBITDA21.1x18.0x(6.7x)(36.2x)18.0x
EV/EBIT25.5x26.2x74.2x43.8x32.1x
EV/Gross Profit8.7x9.2x8.8x9.2x9.2x
P/E32.0x29.3x(5.6x)(20.3x)29.3x
EV/FCF28.8x27.4xn/m37.0x28.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Illumina Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Illumina Margins & Growth Rates

Illumina grew revenue by 5% but EBITDA decreased by 12% in the last fiscal year.

In the most recent fiscal year, Illumina reported gross margin of 66%, EBITDA margin of 34%, and net margin of 20%.

See estimated margins and future growth rates for Illumina

Illumina Margins

Last FY202420252026202720282029
Gross Margin66%65%66%68%
EBITDA Margin34%(17%)34%28%
EBIT Margin23%14%19%23%
Net Margin20%(28%)20%18%
FCF Margin22%16%21%19%

Illumina Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%(5%)(1%)5%
Gross Profit Growth9%(4%)0%9%
EBITDA Growth(12%)(81%)(301%)(12%)
EBIT Growth7%69%36%31%
Net Profit Growth(5%)(72%)(170%)(5%)
FCF Growth(11%)(1058%)31%(9%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Illumina Operational KPIs

Illumina's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Illumina's Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Illumina's Rule of X is 41% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Illumina
LTMLast FY202320242025202620272028
Rule of 4033%33%---
Bessemer Rule of X42%41%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
R&D Expenses to Revenue22%22%29%27%22%
Opex to Revenue-47%57%52%47%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Illumina Competitors

Illumina competitors include Philips, Mettler Toledo, Halma, Mindray, ResMed, GE HealthCare, DexCom, Steris, Sartorius and Exact Sciences.

Most Illumina public comparables operate across Life Sciences Tools, Diagnostics & Genomics, Medical Devices, BioTech, DeepTech and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Philips1.5x1.5x9.1x9.0x
Mettler Toledo6.5x6.3x20.8x20.3x
Halma8.1x7.0x33.2x28.3x
Mindray4.9x4.8x14.3x14.7x
ResMed5.1x4.7x13.6x12.0x
GE HealthCare1.8x1.7x9.7x9.9x
DexCom6.0x5.7x20.5x19.0x
Steris3.7x3.7x13.2x13.0x

This data is available for Pro users. Sign up to see all Illumina competitors and their valuation data.

Start Free Trial

Acquisitions by Illumina

Illumina has acquired 9 companies to date.

Last acquisition by Illumina was on June 23rd 2025. Illumina acquired SomaLogic for $350M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Illumina

SomaLogic
Fluent BioSciences
IDbyDNA
GRAIL
Description
SomaLogic is a Boulder-headquartered proteomics company offering SOMAscan assays for biomarker discovery. Its SOMAmer reagents detect over 7,000 proteins from 100 microliters of sample, applied in oncology, cardiovascular, neurology, and metabolic research. Founded in 1999, the company partners with Pfizer and Novartis and processed samples for over 1 million subjects in studies.
Fluent BioSciences is a Boston-based life sciences firm specializing in single-cell analysis technology. Its PIPseq platform encapsulates individual cells into millions of nanoliter partitions without microfluidics, enabling next-generation sequencing of RNA and proteins. Adopted by biotech firms, pharmaceutical companies like Pfizer, and academic labs at Harvard and MIT, the technology supports high-throughput genomics research for drug discovery and immunology studies.
-
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Boulder, CO
Boston, MA
-
San Francisco, CA
Deal Date23 Jun 20259 Jul 202424 Jun 202221 Sep 2020
Valuation$350Mundisclosedundisclosed$8B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Illumina acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Illumina

Illumina has invested in 1 company to date.

Latest investment by Illumina was on December 11th 2025. Illumina invested in Myome in their Undisclosed stage round.

See VC round multiples

Latest Investments by Illumina

Myome
Description
Myome is a genomics platform that sequences and analyzes whole genomes for disease risk identification. Users store data in a portable format accessible via HIPAA-compliant cloud for lifelong reuse in research matching. Processing occurs at CLIA-certified labs in the US, covering 100 million genetic variants. Founded in 2020 and based in Boston, Myome partners with 23andMe for ancestry-linked health insights.
HQ CountryUnited States
HQ City
San Francisco, CA
Deal Date11 Dec 2025
RoundUndisclosed stage
Raisedundisclosed
InvestorsDuquesne Family Office; Illumina; Natera; Sequoia Capital
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Illumina investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Illumina

When was Illumina founded?Illumina was founded in 1998.
Where is Illumina headquartered?Illumina is headquartered in United States.
How many employees does Illumina have?As of today, Illumina has over 10K employees.
Who is the CEO of Illumina?Illumina's CEO is Jacob Thaysen.
Is Illumina publicly listed?Yes, Illumina is a public company listed on Nasdaq.
What is the stock symbol of Illumina?Illumina trades under ILMN ticker.
When did Illumina go public?Illumina went public in 2000.
Who are competitors of Illumina?Illumina main competitors include Philips, Mettler Toledo, Halma, Mindray, ResMed, GE HealthCare, DexCom, Steris, Sartorius, Exact Sciences.
What is the current market cap of Illumina?Illumina's current market cap is $25B.
What is the current revenue of Illumina?Illumina's last 12 months revenue is $4B.
What is the current revenue growth of Illumina?Illumina revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Illumina?Current revenue multiple of Illumina is 5.9x.
What is the current EBITDA of Illumina?Illumina's last 12 months EBITDA is $1B.
What is Illumina's EBITDA margin?Illumina's last 12 months EBITDA margin is 28%.
What is the current EV/EBITDA multiple of Illumina?Current EBITDA multiple of Illumina is 21.1x.
What is the current FCF of Illumina?Illumina's last 12 months FCF is $912M.
What is Illumina's FCF margin?Illumina's last 12 months FCF margin is 21%.
What is the current EV/FCF multiple of Illumina?Current FCF multiple of Illumina is 28.8x.
How many companies Illumina has acquired to date?As of June 2026, Illumina has acquired 9 companies.
What was the largest acquisition by Illumina?$8B acquisition of GRAIL on 21st September 2020 was the largest M&A Illumina has done to date.
What companies Illumina acquired?Illumina acquired GRAIL, SomaLogic, Bluebee, Edico Genome, GenoLogics, Enancio, Fluent BioSciences, IDbyDNA, and Conexio Genomics.
In how many companies Illumina has invested to date?As of June 2026, Illumina has invested in 1 company.
What was the last Illumina investment?On 11th December 2025 Illumina invested in Myome, participating in a Undisclosed stage round, alongside Duquesne Family Office, Natera, and Sequoia Capital.
In what companies Illumina invested in?Illumina invested in Myome.

See public comps similar to Illumina

Lists including Illumina

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial